

Michael Loken

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10408634/publications.pdf>

Version: 2024-02-01

10
papers

980
citations

1307594

7
h-index

1372567

10
g-index

10
all docs

10
docs citations

10
times ranked

1306
citing authors

#	ARTICLE	IF	CITATIONS
1	Cytarabine dose reduction in patients with low-risk acute myeloid leukemia: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29313.	1.5	5
2	Blood Count Recovery Following Induction Therapy for Acute Myeloid Leukemia in Children Does Not Predict Survival. <i>Cancers</i> , 2022, 14, 616.	3.7	4
3	Outcomes of intensification of induction chemotherapy for children with high-risk acute myeloid leukemia: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29281.	1.5	6
4	Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children's Oncology Group. <i>Haematologica</i> , 2020, 105, 1879-1886.	3.5	83
5	CD33_PGx6_Score Predicts Gemtuzumab Ozogamicin Response in Childhood Acute Myeloid Leukemia: A Report From the Children's Oncology Group. <i>JCO Precision Oncology</i> , 2019, 3, 1-15.	3.0	12
6	Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions. <i>Oncotarget</i> , 2017, 8, 73483-73500.	1.8	153
7	CD33 Expression and Its Association With Gemtuzumab Ozogamicin Response: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531. <i>Journal of Clinical Oncology</i> , 2016, 34, 747-755.	1.6	116
8	Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML. <i>Blood</i> , 2012, 119, 3705-3711.	1.4	91
9	Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. <i>Leukemia Research</i> , 2007, 31, 727-736.	0.8	478
10	Flow Cytometry for Diagnosis and Assessment of Prognosis in Patients with Myelodysplastic Syndromes. <i>Hematology</i> , 2004, 9, 171-177.	1.5	32